Abstract: A process for preparing a compound of formula (I) ##STR1## wherein R is a methylthio, methylsulfoxy, methylsulfonyl or a nitro group; andX4 is --OH, fluorine or --O--SO.sub.2 R6 where R6 is methyl, trifluoromethyl, phenyl or p-methylphenyl which comprises contacting of a compound of formula (III) ##STR2## where R2 is C.sub.1-4 alkyl; and R and X4 have the above mentioned meanings, with a strong base selected from the group consisting of alkali earth metal alcoholates, alkaline earth metal alcoholates, and tertiary amines in an aprotic solvent, to obtain the compound of formula (I).

Abstract: Replacement with fluorine of the primary hydroxy group of 1-phenyl-2-amino-1,3-propanediol compounds wherein the secondary hydroxy group and the amino group have been suitably protected.The reaction is carried out with an inorganic fluoride in a polyglycol.New oxazoline compounds particularly useful in said process.

Abstract: Compounds of formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and X have the meanings reported in the description, can be used in compositions for agricultural use in particular as herbicides in the defense of useful crops from weeds.

Abstract: Compounds of formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and X have the meanings reported in the description, can be used in compositions for agricultural use in particular as herbicides in the defence of useful crops from weeds.

Abstract: Replacement with fluorine of the primary hydroxy group of 1-phenyl-2-amino-1,3-propanediol compounds wherein the secundary hydroxy group and the amino group have been suitably protected.The reaction is carried out with an inorganic fluoride in a polyglycol.New oxazoline compounds particularly useful in said-process.

Abstract: Intermediates of Formula ##STR1## where R is a methylthio, methylsulfoxy, methylsulfonyl or a nitro group; andX1 is hydrogen, 1-6 C alkyl, 1-6 C haloalkyl, 3-6 C cycloalkyl, phenyl or phenylalkyl(1-6 C), where the phenyl ring may be substituted by one or two halogen, 1-3 C alkyl, 1-3 C alkoxy or nitro; orX1 together with X2 is an oxygen atom or an alkylene having from two to five Carbon atoms; orX1 together with X2 and R4 is a chain of formula ##STR2## where p is 3 or 4 and q is 1 or 2; and X2 is hydrogen, 1-6 C alkyl, 1-6 C haloalkyl, 3-6 C cycloalkyl or phenyl which may be substituted by one or two halogen, 1-3 C alkyl, 1-3 C alkoxy or nitro; orX2 together with X1 has the above mentioned meanings; orX2 together with R4 is --(CH.sub.2).sub.m --CH.dbd.CH--; --(CH.sub.2).sub.m --CH.sub.2 --CH.sub.

Abstract: A diastereoselective process for the preparation of compounds of formula ##STR1## (wherein R and R.sub.1 have the meanings reported in the specification and the asterisks show the asymmetric carbon atoms) starting from the corresponding N-protected 2-amino-3-aryl-propan-1-ol is described.The compounds of formula I are intermediates useful for the synthesis of pharmacologically active peptides.

Abstract: Intermediates having the formula ##STR1## wherein R is --NO.sub.2, CH.sub.3 S--, CH.sub.3 SO--, or CH.sub.3 SO.sub.2 --, X.sub.1 is hydrogen, alkyl, haloalkyl, (substituted) phenyl or phenylalkyl and Y is F or --OSO.sub.2 R.sub.6 wherein R.sub.6 is methyl, trifluoromethyl, (substituted) phenyl naphthyl or pyridyl are disclosed.

Abstract: Compounds of the formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and n have the meanings reported in the specification, processes for their preparation and pharmaceutical compositions containing them as active ingredient are described.The compounds of formula I are inhibitor of enzymatic systems and they are useful in pharmaceutical field.

Abstract: A stereoselective process for the preparation of the compounds of formula ##STR1## wherein R, R.sub.1, R.sub.2, a and b have the meanings reported in the specification, is described.The compounds of formula I have a remarkable central analgesic activity and they are useful in the pharmaceutical field.

Abstract: Intermediates of Formula ##STR1## where R is a methylthio, methylsulfoxy, methylsulfonyl or a nitro group; andX1 is hydrogen, 1-6 C alkyl, 1-6 C haloalkyl, 3-6 C cycloalkyl, phenyl or phenylalkyl(1-6C), where the phenyl ring may be substituted by one or two halogen, 1-3 C alkyl, 1-3 C alkoxy or nitro; orX1 together with X2 is an oxygen atom or an alkylene having from two to five Carbon atoms; orX1 together with X2 and R4 is a chain of formula ##STR2## where p is 3 or 4 and q is 1 or 2; and X2 is hydrogen, 1-6 C alkyl, 1-6 C haloalkyl, 3-6 C cycloalkyl or phenyl which may be substituted by one or two halogen, 1-3 C alkyl, 1-3 C alkoxy or nitro; orX2 together with R4 is ##STR3## where n is 1 or 2; m is 0 or 1; X is hydrogen, halogen, 1-3 C alkyl, 1-3 C alkoxy or nitro; andX3 is hydrogen or --CO--R4 where R4 is hydrogen, 1-6 alkyl, 1-6 C haloalkyl, 3-6 C cycloalkyl, phenylalkyl(1-6C) or phenyl where the phenyl ring may be substituted by one or two halogen, 1-3 alkyl, 1-3 alkoxy or nitro; andX4 is --OH, fluorine,

Abstract: The blood level of orally administered N-acetylcysteine is substantially increased in a mammal when the N-acetylcysteine is administered in combination with tris(hydroxymethyl)aminomethane or a pharmaceutically acceptable salt thereof, in a molar ratio of about 1:0.8 to about l:l.2.

Abstract: Compounds of formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and n have the meanings reported in the specification, processes for their preparation and pharmaceutical compositions containing them as active ingredient are described. The compounds of formula I are inhibitors of enzymatic systems and they are useful in pharmaceutical field.

Abstract: Compounds of formula ##STR1## (wherein R, R.sub.1, R.sub.2 and Y have the meanings indicated in the description), a process for the preparation thereof and pharmaceutical compositions containing them as active ingredient are described.Compounds of formula I exhibit anto-serotonin activity.

Abstract: Nootropically active isoxazoles which are certain specified derivatives of N-(5-isoxazolecarbonyl)-4 aminobutyric acid.

Abstract: Compounds of formula ##STR1## (wherein R, R.sub.1, R.sub.2, R.sub.3 and n have the meanings reported in the specification), their salts with pharmaceutically acceptable acids, process for their preparation and pharmaceutical compositions containing them are described.The compounds of formula I have a remarkable analgesic activity.

Abstract: Compounds of the formula ##STR1## wherien R, R.sub.1, R.sub.2 and Y have the meanings mentioned in the description, processes for their preparation and their use in the pharmaceutical field are described.The compounds of formula I are endowed with antipyretic, anti-inflammatory, mucolitic and analgesic activity together with good gastric tolerability.In addition, the compounds of formula I are active in the treatment of ischemic or reperfusion syndromes.

Abstract: The compound N-[(1S,2R)-fluoromethyl-2-hydroxy-2-(4-methylsulphonyl-phenyl)-ethyl]-2-pr openamide and the derivatives thereof in which the hydroxy in 2 position is esterified by a mono or dicarboxylic acid or by an aminoacid are described.Such compounds have antibiotic activity and are useful in human and veterinary therapy.

Abstract: Compounds of formula ##STR1## (wherein R, R.sub.1 and R.sub.2 have the meanings reported in the specification) and their preparation are described.The compounds of formula I have anti-allergic, anti-anaphylactic and anti-arthritic activity and are useful in pharmaceutical field.Compositions for pharmaceutical use containing a compound of formula I as active ingredient are described too.

Abstract: Preparation of alkyl fluoride by replacement of an aliphatic hydroxy group with fluorine. The reaction is performed by treating a sulfonyl derivative of an aliphatic hydroxy group with an inorganic fluoride in a polyglycol.